RT Journal Article
T1 Infective endocarditis in hypertrophic cardiomyopathy: A multicenter, prospective, cohort study.
A1 Dominguez, Fernando
A1 Ramos, Antonio
A1 Bouza, Emilio
A1 Muñoz, Patricia
A1 Valerio, Maricela C
A1 Fariñas, M Carmen
A1 de Berrazueta, José Ramón
A1 Zarauza, Jesús
A1 Pericás Pulido, Juan Manuel
A1 Paré, Juan Carlos
A1 de Alarcón, Arístides
A1 Sousa, Dolores
A1 Rodriguez Bailón, Isabel
A1 Montejo-Baranda, Miguel
A1 Noureddine, Mariam
A1 García Vázquez, Elisa
A1 Garcia-Pavia, Pablo
AB Infective endocarditis (IE) complicating hypertrophic cardiomyopathy (HCM) is a poorly known entity. Although current guidelines do not recommend IE antibiotic prophylaxis (IEAP) in HCM, controversy remains.This study sought to describe the clinical course of a large series of IE HCM and to compare IE in HCM patients with IE patients with and without an indication for IEAP.Data from the GAMES IE registry involving 27 Spanish hospitals were analyzed. From January 2008 to December 2013, 2000 consecutive IE patients were prospectively included in the registry. Eleven IE HCM additional cases from before 2008 were also studied. Clinical, microbiological, and echocardiographic characteristics were analyzed in IE HCM patients (n = 34) and in IE HCM reported in literature (n = 84). Patients with nondevice IE (n = 1807) were classified into 3 groups: group 1, HCM with native-valve IE (n = 26); group 2, patients with IEAP indication (n = 696); group 3, patients with no IEAP indication (n = 1085). IE episode and 1-year follow-up data were gathered.One-year mortality in IE HCM was 42% in our study and 22% in the literature. IE was more frequent, although not exclusive, in obstructive HCM (59% and 74%, respectively). Group 1 exhibited more IE predisposing factors than groups 2 and 3 (62% vs 40% vs 50%, P 
YR 2016
FD 2016
LK http://hdl.handle.net/10668/10231
UL http://hdl.handle.net/10668/10231
LA en
DS RISalud
RD Jul 7, 2025